Strategies by Key Players Along with Rising Geriatric Population to Drive the Indian Diabetes Diagnosis and Therapeutics Market.

The Indian diabetes diagnosis and therapeutics market are anticipated to grow at a CAGR of 7% during the forecast period. The major factor driving the growth of the Indian diabetes diagnosis and therapeutics market during the forecast period is the rising prevalence of the geriatric population in the country. According to the National Commission on Population 2020 report, it was estimated that there will be nearly 138 million elderly persons in India in 2021 which will comprise 67 million males and 71 million females. Additionally, as per the same source, the growth rate of the elderly population is higher than that of the general population.

Browse the full report description of "Indian Diabetes Diagnosis and Therapeutics Market Size, Share & Trends Analysis Report by Disease Type (Type 1 Diabetes, Type 2 Diabetes, and Gestational), by Drug Type (Oral anti-diabetic Drugs, Non-Insulin Injectable drugs, and Combination Drugs), and by Device Type (Blood Glucose Monitoring Devices, Blood Glucose Strips, Insulin devices, and Others) Forecast Period (2022-2028)" at https://www.omrglobal.com/industry-reports/indian-diabetes-diagnosis-and-treatment-market

Moreover, the growth of the market is attributed to the strategies such as new launches, partnerships, mergers, and acquisitions by key players in the market.

• In January 2022, Novo Nordisk India announced the launch of a first-of-its-kind diabetes treatment oral medication semaglutide in India. Semaglutide is a GLP-1 receptor analog (GLP-1 RA) one of the drug classes to treat diabetes
• In October 2021, Glenmark Pharmaceuticals Ltd launched a fixed-dose combination (FDC) drug for the management of Type 2 diabetes in India.
• In July 2021, Novo Nordisk developed and launched two anti-diabetes medications from its global portfolio in India in 2022. The two medications include different formulations of Semiglutide or a glucagon-like peptide-1 (GLP-1) molecule and Rybelsus, an incretin mimic in a pill form. Rybelsus is used to improve the control of blood sugar in adult patients with type 2 diabetes.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Disease Type
• By Drug Type
• By Device Type

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Elli Lilly and Co., Merck & Co., Inc., Novartis International AG, Pfizer Inc., and Glenmark Pharmaceuticals Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

oDeviation from the pre-COVID-19 forecast

oMost affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Indian Diabetes Diagnosis and Therapeutics Market Report by Segment

By Disease Type

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational 

By Drug Type

• Oral anti-diabetic Drugs
• Non-Insulin Injectable drugs
• Combination Drugs

By Device Type

• Blood Glucose Monitoring Devices
• Blood Glucose Strips
• Insulin devices 
• Others

To learn more about this report request a free sample copy @ https://www.omrglobal.com/industry-reports/indian-diabetes-diagnosis-and-treatment-market